These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27358496)

  • 21. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prioritization of livestock transboundary diseases in Belgium using a multicriteria decision analysis tool based on drivers of emergence.
    Bianchini J; Humblet MF; Cargnel M; Van der Stede Y; Koenen F; de Clercq K; Saegerman C
    Transbound Emerg Dis; 2020 Jan; 67(1):344-376. PubMed ID: 31520577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions.
    Jauregui B; Janusz CB; Clark AD; Sinha A; Garcia AG; Resch S; Toscano CM; Sanderson C; Andrus JK
    Vaccine; 2015 May; 33 Suppl 1():A21-7. PubMed ID: 25919164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incorporating economic evaluation into immunization decision making in Canada: a workshop.
    Langley JM; Krahn M; Husereau D; Spika J; Fisman DN; Chit A; Van Exan R
    Expert Rev Vaccines; 2014 Nov; 13(11):1291-6. PubMed ID: 25052459
    [No Abstract]   [Full Text] [Related]  

  • 25. New vaccine adoption: qualitative study of national decision-making processes in seven low- and middle-income countries.
    Burchett HE; Mounier-Jack S; Griffiths UK; Biellik R; Ongolo-Zogo P; Chavez E; Sarma H; Uddin J; Konate M; Kitaw Y; Molla M; Wakasiaka S; Gilson L; Mills A
    Health Policy Plan; 2012 May; 27 Suppl 2():ii5-16. PubMed ID: 22513732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A crisis of public confidence in vaccines.
    Black S; Rappuoli R
    Sci Transl Med; 2010 Dec; 2(61):61mr1. PubMed ID: 21148125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimated impact and cost-effectiveness of rotavirus vaccination in India: effects of geographic and economic disparities.
    Rheingans R; Anderson JD; Anderson B; Chakraborty P; Atherly D; Pindolia D
    Vaccine; 2014 Aug; 32 Suppl 1():A140-50. PubMed ID: 25091669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Basis for vaccine recommendations].
    Lévy-Bruhl D
    Med Sci (Paris); 2007 Apr; 23(4):404-8. PubMed ID: 17433231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
    Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
    Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developing vaccines for an aging population.
    Black S; De Gregorio E; Rappuoli R
    Sci Transl Med; 2015 Apr; 7(281):281ps8. PubMed ID: 25834107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do we fully understand the economic value of vaccines?
    Drummond M; Chevat C; Lothgren M
    Vaccine; 2007 Aug; 25(32):5945-57. PubMed ID: 17629362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling prioritized multicriteria decision making.
    Yager RR
    IEEE Trans Syst Man Cybern B Cybern; 2004 Dec; 34(6):2396-404. PubMed ID: 15619938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discrepancies between multicriteria decision analysis-based ranking and intuitive ranking for pharmaceutical benefit-risk profiles in a hypothetical setting.
    Hoshikawa K; Ono S
    J Clin Pharm Ther; 2017 Feb; 42(1):80-86. PubMed ID: 27914099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The National Committee for Vaccines Regulation and Surveillance of Vaccine-Preventable Diseases in the Sultanate of Oman: evidence-based approach and consensus decision-making.
    Al Awaidy S
    Vaccine; 2010 Apr; 28 Suppl 1():A39-41. PubMed ID: 20412995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prioritization of the introduction of new vaccines to the national immunization program in the Republic of Korea.
    Choe YJ; Han OP; Cho H; Bae GR; Chun BC; Kim JH; Kim KH; Lee HJ; Choi EH
    Vaccine; 2014 Oct; 32(46):6049-53. PubMed ID: 25239482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging issues in vaccine economics: perspectives from the USA.
    Lieu TA; Thompson KM; Prosser LA; O'Brien MA; Yusuf HR; Shefer AM; Weinstein MC; Rickert DL
    Expert Rev Vaccines; 2002 Dec; 1(4):433-42. PubMed ID: 12901581
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction.
    Shen AK; Weiss JM; Andrus JK; Pecenka C; Atherly D; Taylor K; McQuestion M
    Health Aff (Millwood); 2016 Feb; 35(2):272-6. PubMed ID: 26858380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. National Advisory Groups and their role in immunization policy-making processes in European countries.
    Nohynek H; Wichmann O; D Ancona F;
    Clin Microbiol Infect; 2013 Dec; 19(12):1096-105. PubMed ID: 23957860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New vaccine adoption in lower-middle-income countries.
    Makinen M; Kaddar M; Molldrem V; Wilson L
    Health Policy Plan; 2012 May; 27 Suppl 2():ii39-49. PubMed ID: 22513731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives on expanding the evidence base to inform vaccine introduction: Program costing and cost-effectiveness analyses.
    Andrus JK; Walker DG
    Vaccine; 2015 May; 33 Suppl 1():A2-3. PubMed ID: 25919161
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.